These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 23140527)

  • 21. Low-Molecular-Weight Heparin and the Relative Risk of Surgical Site Bleeding Complications: Results of a Systematic Review and Meta-Analysis of Randomized Controlled Trials of Venous Thromboprophylaxis in Patients After Total Joint Arthroplasty.
    Suen K; Westh RN; Churilov L; Hardidge AJ
    J Arthroplasty; 2017 Sep; 32(9):2911-2919.e6. PubMed ID: 28522244
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Direct factor Xa inhibitors (rivaroxaban and apixaban) versus enoxaparin for the prevention of venous thromboembolism after total knee replacement: A meta-analysis of 6 randomized clinical trials.
    Ma G; Zhang R; Wu X; Wang D; Ying K
    Thromb Res; 2015 May; 135(5):816-22. PubMed ID: 25728496
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparative effectiveness of direct oral anticoagulants versus low-molecular weight heparins for the prevention of venous thromboembolism after total hip or knee replacement: A nationwide database cohort study.
    Blin P; Samama CM; Sautet A; Benichou J; Lignot-Maleyran S; Lamarque S; Lorrain S; Lassalle R; Droz-Perroteau C; Mismetti P; Moore N
    Pharmacol Res; 2019 Mar; 141():201-207. PubMed ID: 30583081
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of oral factor Xa inhibitor and low-molecular-weight heparin on surgical complications following total hip arthroplasty.
    Kim SM; Moon YW; Lim SJ; Kim DW; Park YS
    Thromb Haemost; 2016 Mar; 115(3):600-7. PubMed ID: 26790579
    [TBL] [Abstract][Full Text] [Related]  

  • 25. New options for anticoagulation following total hip arthroplasty and total knee arthroplasty: new oral agents on the horizon.
    Amin A
    Hosp Pract (1995); 2012 Aug; 40(3):19-26. PubMed ID: 23086091
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Direct inhibitors of coagulation proteins - the end of the heparin and low-molecular-weight heparin era for anticoagulant therapy?
    Laux V; Perzborn E; Heitmeier S; von Degenfeld G; Dittrich-Wengenroth E; Buchmüller A; Gerdes C; Misselwitz F
    Thromb Haemost; 2009 Nov; 102(5):892-9. PubMed ID: 19888525
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Thromboprophylaxis with enoxaparin and direct oral anticoagulants in major orthopedic surgery and acutely ill medical patients: a meta-analysis.
    Cimminiello C; Prandoni P; Agnelli G; Di Minno G; Polo Friz H; Scaglione F; Boracchi P; Marano G; Harenberg J
    Intern Emerg Med; 2017 Dec; 12(8):1291-1305. PubMed ID: 28756546
    [TBL] [Abstract][Full Text] [Related]  

  • 28. New oral anticoagulants for thromboprophylaxis after total hip or knee arthroplasty.
    Friedman RJ
    Orthopedics; 2009 Dec; 32(12 Suppl):79-84. PubMed ID: 20201481
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison between use of direct oral anticoagulants and aspirin for risk of thromboembolism complications in patients undergoing total knee and hip arthroplasty: a systematic review and meta-analysis.
    Cai JY; Cui CM; Min JK; Cao YQ; Zhang LY
    Eur Rev Med Pharmacol Sci; 2021 Oct; 25(20):6245-6259. PubMed ID: 34730204
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Benefit and risk of primary thromboprophylaxis in ambulatory patients with advanced pancreatic cancer receiving chemotherapy: a systematic review and meta-analysis of randomized controlled trials.
    Tun NM; Guevara E; Oo TH
    Blood Coagul Fibrinolysis; 2016 Apr; 27(3):270-4. PubMed ID: 26963028
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Oral direct factor Xa inhibition with edoxaban for thromboprophylaxis after elective total hip replacement. A randomised double-blind dose-response study.
    Raskob G; Cohen AT; Eriksson BI; Puskas D; Shi M; Bocanegra T; Weitz JI
    Thromb Haemost; 2010 Sep; 104(3):642-9. PubMed ID: 20589317
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A meta-analysis comparing low-molecular-weight heparins with unfractionated heparin in the treatment of venous thromboembolism: examining some unanswered questions regarding location of treatment, product type, and dosing frequency.
    Dolovich LR; Ginsberg JS; Douketis JD; Holbrook AM; Cheah G
    Arch Intern Med; 2000 Jan; 160(2):181-8. PubMed ID: 10647756
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Apixaban and rivaroxaban decrease deep venous thrombosis but not other complications after total hip and total knee arthroplasty.
    Russell RD; Huo MH
    J Arthroplasty; 2013 Oct; 28(9):1477-81. PubMed ID: 23540535
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Rivaroxaban Versus Enoxaparin for Venous Thromboembolism Prophylaxis after Hip and Knee Arthroplasty.
    Charters MA; Frisch NB; Wessell NM; Dobson C; Les CM; Silverton CD
    J Arthroplasty; 2015 Jul; 30(7):1277-80. PubMed ID: 25724111
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Wound complications and bleeding with new oral anticoagulants in patients undergoing total joint arthroplasty: A systematic review and meta-analysis of randomized controlled trials.
    Wang M; Xie J; Zheng H; Wang S; Zhou R; Li W; Xue E; Wang X; Jiang J; Wu T; Zhan S
    Br J Clin Pharmacol; 2022 Feb; 88(2):500-513. PubMed ID: 34322914
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of pharmacologic prophylaxis in prevention of venous thromboembolism following total knee arthroplasty.
    Richardson SS; Schairer WW; Sculco PK; Bostrom MP
    Knee; 2019 Mar; 26(2):451-458. PubMed ID: 30700390
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Incremental net monetary benefit of direct oral anticoagulants for the prevention of venous thromboembolism after total knee or hip replacement: A systematic review and meta-analysis.
    Veettil SK; Harris J; Syeed MS; Thakkinstian A; Chaikledkaew U; Witt DM; Chaiyakunapruk N
    Thromb Res; 2022 Aug; 216():74-83. PubMed ID: 35753113
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Enoxaparin versus dabigatran or rivaroxaban for thromboprophylaxis after hip or knee arthroplasty: Results of separate pooled analyses of phase III multicenter randomized trials.
    Huisman MV; Quinlan DJ; Dahl OE; Schulman S
    Circ Cardiovasc Qual Outcomes; 2010 Nov; 3(6):652-60. PubMed ID: 20923996
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical experience with ximelagatran in orthopaedic surgery.
    Eriksson B
    Drugs; 2004; 64 Suppl 1():27-35. PubMed ID: 15586625
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The effect of anti-Xa monitoring on the safety and efficacy of low-molecular-weight heparin anticoagulation therapy: A systematic review and meta-analysis.
    Wu T; Xia X; Chen W; Fu J; Zhang J
    J Clin Pharm Ther; 2020 Aug; 45(4):602-608. PubMed ID: 32449992
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.